STOCK TITAN

VBI Vaccines Inc. - VBIV STOCK NEWS

Welcome to our dedicated news page for VBI Vaccines (Ticker: VBIV), a resource for investors and traders seeking the latest updates and insights on VBI Vaccines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VBI Vaccines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VBI Vaccines's position in the market.

Rhea-AI Summary
VBI Vaccines announces positive interim data from Phase 1 clinical study of its pan-coronavirus vaccine candidate, VBI-2901. High and sustained neutralizing responses observed against COVID-19 variants and animal coronaviruses. Durability of immune responses maintained at 6 months. Safety profile consistent with VBI's eVLP platform. Funding available for next phase of clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
none
-
Rhea-AI Summary
VBI Vaccines initiates Phase 2b study of cancer vaccine VBI-1901 in patients with recurrent glioblastoma (rGBM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
-
Rhea-AI Summary
BRII-179 (VBI-2601) shows positive results in Phase 2 study for hepatitis B treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
Rhea-AI Summary
Brii Bio announces positive results for BRII-179 in Phase 2 study for chronic hepatitis B
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Brii Biosciences reports positive interim results and updates on its therapies for HBV and PPD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
-
Rhea-AI Summary
VBI Vaccines Inc. (Nasdaq: VBIV) announces the launch of PreHevbri®, the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium. The product will be available through a marketing and distribution partnership with Valneva. PreHevbri® is designed for active immunization against all known subtypes of the hepatitis B virus (HBV) in adults, with potential prevention of hepatitis D as well. This move aims to expand global access to PreHevbri in the fight against hepatitis B worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.24%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.24%
Tags
none
VBI Vaccines Inc.

Nasdaq:VBIV

VBIV Rankings

VBIV Stock Data

16.42M
20.44M
7.69%
11.84%
1.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Cambridge

About VBIV

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.